Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN versus YUVIWEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN versus YUVIWEL.
TRAVATAN vs YUVIWEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix in the ciliary body.
YUVIWEL (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces the uptake of monoamines (such as dopamine) into synaptic vesicles, thereby decreasing their release into the synaptic cleft, which reduces dopaminergic transmission implicated in hyperkinetic movement disorders.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
No established standard dosing for YUVIWEL; drug not recognized.
None Documented
None Documented
Terminal elimination half-life is approximately 45 minutes for travoprost acid (active metabolite). Clinical context: due to rapid systemic clearance, ocular hypotensive effect persists for 24 hours from corneal tissue binding.
Terminal elimination half-life is 12 hours; steady-state reached within 48-60 hours, requiring dose adjustment in renal impairment.
Renal (primarily as metabolites): ~70%; Fecal: ~25%; Unchanged drug in urine: <1%
Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination constitutes 30%.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog